Company: TXG
Filing Date: 2025-05-09
Form Type: 10-Q
Source: 0001770787-25-000032
Chunk: 59

Company: 10x Genomics, Inc.
Filing Date: 2025-05-09
Form: 10-Q
Item: Part I, Item 8
Chunk 59
---
, including potential freezes of, reductions in or reduced availability of U.S. academic and government research funding, including funding from the National Institutes of Health (NIH) or other sources for our customers; 

•the effects of competition, including competition with both new and existing companies offering products that compete or intend to compete with our products and may offer performance, price or other advantages as well as researchers developing their own solutions; 

•the timing and magnitude of our price changes, including the effects of potentially lowering prices for certain of our products in 2025;

•trade tariffs, import restrictions, export restrictions, Chinese regulations or other trade barriers, including retaliatory measures taken by trade partners; 

•modifications to our commercial processes and organization, including changes we made to our commercial processes and organization to increase effectiveness; 

•fluctuations in demand for our products, which may vary significantly, our ability to accurately forecast demand, and our ability to increase penetration with our existing customers and to expand to new customers;

•changes in general market conditions and other factors, including factors unrelated to our operating performance or the performance of our competitors;

•the effects of inflation on us or our customers, manufacturers and suppliers, including increases in the cost of labor and materials, including as a result of tariffs imposed by the United States which are currently, or in the future, under consideration, proposed or enacted;

•excess capacity expenses and inventory write-downs; 

•changes in volume and product mix, particularly from products with lower gross margins than other products that we sell, or changes in costs related to our instruments and consumables, including products which incur royalty payment obligations at higher rates than other products we sell;

•the success of our recently introduced and recently announced products and new versions of existing products, and our ability to generate revenue for such products, and the introduction of new products or product enhancements by us or others in our industry including the timing of such introductions;

•disruptions in customers’ on-going experiments or interruptions in the ability of our customers to complete research projects;

•investment decisions we make with respect to the allocation of our resources, including regarding product development or to support our commercial organization;

•risks related to our business and demand for our products in China and elsewhere in the Asia-Pacific region, including competition or other factors;

•differences in purchasing patterns across our customer base or across our two portfolios and variances in consumables spending for each of our portfolios;

•higher than anticipated warranty costs;

•the timing and amount of expenditures that we